Uso Amiodarona

Use of Amiodarone
Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.
To the Editor: In their Clinical Review, Drs Vassallo and Trohman1 examined the role of amiodarone in different clinical settings and, in particular, suggested that "amiodarone can be used safely in patients with left ventricular dysfunction and CHF [congestive heart failure]." However, the authors did not provide a complete analysis of the relevant clinical trials.
In the GESICA trial,2 amiodarone reduced mortality, but that study was conducted in a single country, so its results may not be applicable to a broader spectrum of populations with a diverse natural history of CHF. In addition, GESICA had not been blinded. This shortcoming, along with the observation of an unexpectedly low drop-out rate (3%) despite amiodarone's well-known toxicity, suggest that the results should be viewed with caution.
The CHF-STAT study3 was placebo-controlled but had other limitations that could have affected the purported neutral effect on survival: small patient population, limited follow-up, and lack . . . [Full Text of this Article]
Michele Coceani, MD
michecoc@ifc.cnr.it
CNR Institute of Clinical Physiology
Pisa, Italy






RELATED LETTERS


Use of Amiodarone
John R. Kapoor
JAMA. 2007;298(22):2617.
EXTRACT | FULL TEXT

Use of Amiodarone—Reply
Patricia Vassallo and Richard G. Trohman
JAMA. 2007;298(22):2618.
EXTRACT | FULL TEXT

http://jama.ama-assn.org/cgi/content/extract/298/22/2617-a